MBD4, methyl-CpG binding domain protein 4 (MED1), is part of the mammalian DNA glycosylase superfamily. MBD4 may be involved in maintaining genome stability, epigenetics via DNA methylation, as well as carcinogenesis. MBD4 has an amino-proximal methyl-CpG binding domain and a C-terminal mismatch-specific glycosylase domain. This configuration is thought to help maintain genome stability (PMID: 21820404). Proteins with methylcytosine-binding domains act as transcriptional repressors via promoter methylation, as well as promote the gene-silencing effect of DNA methylation. A study of patients with primary immune thrombocytopenia has shown that a decrease in expression of MBD4 may be involved with the pathogenesis of the disease (PMID: 21377502). Additionally, MBD4 has been shown to be a human DNA repair protein that is possibly involved in DNA mismatch repair. Furthermore, a study investigating microsatellite instability found that the MBD4 codon 346 polymorphism may be a factor in colorectal cancer susceptibility in the Korean population (PMID: 19469655).

This MBD4 antibody is useful for Immunocytochemistry/Immunofluorescence and IHC-paraffin embedded sections. In ICC/IF, nuclear staining was observed in HeLa cells. In IHC-P, staining was observed in the nucleus of human breast cancer tissue. Prior to immunostaining paraffin tissues, antigen retrieval with sodium citrate buffer (pH 6.0) is recommended. This antibody is not applicable for Western Blot.